TARDBP and amyotrophic lateral sclerosis: Fortunately, the former, a phase 2a clinical trial, showed promising results suggesting Apilimod dimesylate might have an impact on all forms of ALS, not merely C9orf72-ALS, and might reverse the prevalent TDP-43-associated pathology.